Search research articles
Contact Us
Filters
Showing results (111-120 of 134) with videos related to
Page
of 14
Sort By:
The Journal of Investigative Dermatology
|
February 21, 2021
Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach
Kevin B Kim, Liliana Soroceanu, David de Semir, et al.
BMC Cancer
|
January 6, 2022
The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma
Georgia Sofia Karachaliou, Rached Alkallas, Sarah B Carroll, et al.
The New England Journal of Medicine
|
October 2, 2012
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Keith T Flaherty, Jeffery R Infante, Adil Daud, et al.
Oncotarget
|
May 19, 2015
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
Filip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Melanoma Research
|
May 12, 2009
A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence
Kevin B Kim, Sewa S Legha, Rene Gonzalez, et al.
Oncotarget
|
September 26, 2015
Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
Filip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
British Journal of Cancer
|
December 21, 2019
Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies
Ryan J Ice, Michelle Chen, Max Sidorov, et al.
Cancer
|
November 2, 2018
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies
Minny Bhatty, Shumei Kato, Sarina A Piha-Paul, et al.
The Lancet. Oncology
|
July 19, 2012
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S Falchook, Karl D Lewis, Jeffrey R Infante, et al.
Elife
|
November 7, 2013
BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling
Harina Vin, Sandra S Ojeda, Grace Ching, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 134) with videos related to
Sort By:
Page
of 14
The Journal of Investigative Dermatology
|
February 21, 2021
Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach
Kevin B Kim, Liliana Soroceanu, David de Semir, et al.
BMC Cancer
|
January 6, 2022
The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma
Georgia Sofia Karachaliou, Rached Alkallas, Sarah B Carroll, et al.
The New England Journal of Medicine
|
October 2, 2012
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Keith T Flaherty, Jeffery R Infante, Adil Daud, et al.
Oncotarget
|
May 19, 2015
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
Filip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Melanoma Research
|
May 12, 2009
A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence
Kevin B Kim, Sewa S Legha, Rene Gonzalez, et al.
Oncotarget
|
September 26, 2015
Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
Filip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
British Journal of Cancer
|
December 21, 2019
Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies
Ryan J Ice, Michelle Chen, Max Sidorov, et al.
Cancer
|
November 2, 2018
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies
Minny Bhatty, Shumei Kato, Sarina A Piha-Paul, et al.
The Lancet. Oncology
|
July 19, 2012
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S Falchook, Karl D Lewis, Jeffrey R Infante, et al.
Elife
|
November 7, 2013
BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling
Harina Vin, Sandra S Ojeda, Grace Ching, et al.
Page
of 14